|
|
||||||||
From the Réseau de Neuroimmunologie du Nerf Périphérique (AP/HP) (Drs. Créange, Chazaud, Plonquet, Sharshar, Raphaël, and Gherardi, and F. Poron, and C. Sonnet), INSERM E.0011 (Drs. Créange, Chazaud, Plonquet, Sharshar, Raphaël, and Gherardi, and F. Poron, and C. Sonnet), Service de Neurologie (Dr. C
eange), Département de Pathologie (Dr. Gherardi), Service dImmunologie-Biologique, Centre Hospitalier Universitaire Henri Mondor (Dr. Plonquet), Créteil, and Service de Réanimation Médicale, Hôpital Raymond Poincaré, (Drs. Sharshar and Raphaël), Garches, France.
Address correspondence and reprint requests to Dr. A. Créange, Service de Neurologie, Hôpital Henri Mondor, AP-HP et Université Paris XII, 94010 Créteil Cedex, France; e-mail: creange{at}univ-paris12.fr
The adhesion capacities, transmigration capacities, and integrin expression of lymphocytes from patients with GuillainBarré syndrome incubated with interferon-ß were studied. Interferon-ß induced a dose-dependent inhibition of lymphocyte adhesion to recombinant vascular adhesion molecule-1 (p < 0.0001) and recombinant intercellular adhesion molecule-1 (rICAM-1) (p < 0.01) without modulation of very late activation molecule-4 and lymphocyte function-associated antigen-1 expressions and a dose-dependent decrease of lymphocyte transmigration across fibronectin (p < 0.0001). Inhibition of adhesion to rICAM-1 was similar after long (18 hours) or short (5 minutes) incubation time. These results support the potential therapeutic benefit of interferon-ß in GuillainBarré syndrome.
This article has been cited by other articles:
![]() |
E. Waubant, D. Goodkin, A. Bostrom, P. Bacchetti, J. Hietpas, R. Lindberg, and D. Leppert IFN{beta} lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS Neurology, January 14, 2003; 60(1): 52 - 57. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |